Could a Copper-Lowering drug help stop Triple-Negative breast cancer recurrence?
NCT ID NCT06134375
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a drug called tetrathiomolybdate (TM) to standard chemotherapy (capecitabine) can reduce the risk of cancer spreading in people with high-risk triple-negative breast cancer. The trial has two parts: first, a small safety phase, then a larger randomized phase comparing the combination to capecitabine alone. About 204 participants who have completed initial treatment but still have signs of residual disease will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tetrathiomolybdate (TM) and capecitabine
What this could lead to
If successful, this could lead to a new treatment option that lowers the chance of breast cancer spreading in patients at high risk of relapse.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are not proven yet. Adding TM may cause side effects or not improve outcomes over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University Simon Cancer Center
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
-
NYU Langone perimutter Cancer Center
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact